Clinical Trial

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

Recruiting
View on ClinicalTrials.gov →
Summary
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-05.
Trial Details
NCT Number NCT06676527
Lead Sponsor Jinling Hospital, China
Conditions Neoplasms, Kidney Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases, Urogenital Diseases, Kidney Diseases +5 more
Enrollment 39 participants
Start Date 2024-09-01
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-05